Robert M. Conry

7.0k citations

87 papers · 3.3k indexed · h-index 31

Oncology top 1%
- CAR-T cell therapy research 24
- Cancer Immunotherapy and Biomarkers 20
- Cutaneous Melanoma Detection and Management 13
Immunology top 2%
- Immunotherapy and Immune Responses 28
Molecular Biology top 5%
- Melanoma and MAPK Pathways 14
- RNA Interference and Gene Delivery 6
Biotechnology top 5%
Genetics top 5%
- Virus-based gene therapy research 12
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 10

Co-authors: Albert F. LoBuglio Svetlana B. McKee Brian C. Westbrook T. Graham Norwood M.B. Khazaeli Agop Y. Bedikian Susan E. Moore David T. Curiel
Cited by: Oncology Immunology Molecular Biology
Journals: Journal of Clinical Oncology (22 papers)Journal of Immunotherapy (6 papers)Annals of Oncology (5 papers)
Partner nations: United States Australia Germany

In The Last Decade

Robert M. Conry

84 papers receiving 3.2k citations

Peers

Countries citing papers authored by Robert M. Conry

Since Specialization

Citations

This map shows the geographic impact of Robert M. Conry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Conry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Conry more than expected).

Fields of papers citing papers by Robert M. Conry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Conry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Conry. The network helps show where Robert M. Conry may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Robert M. Conry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert M. Conry Line = papers co-authored together Robert M. Conry links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 Clinical Cancer Research ·Mansoor N. Saleh,Manish R. Patel,Todd M. Bauer,Sanjay Goel,Gerald S. Falchook,Geoffrey I. Shapiro,Ki Y. Chung,Jeffrey R. Infante,Robert M. Conry,Guilherme Rabinowits,David S. Hong,Judy S. Wang,Ulrich Steidl,Gurudatta Naik,Vincent Guerlavais,Vojislav Vukovic,D. Allen Annis,Manuel Aivado,Funda Meric‐Bernstam	2021	110
2	Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial Nature Medicine ·Reinhard Dummer,David Gyorki,John Hyngstrom,Adam C. Berger,Robert M. Conry,Lev Demidov,Anjali Sharma,Sheryl Treichel,Hoi-Shen Radcliffe,Kevin Gorski,Abraham Anderson,Emily Chan,Mark B. Faries,Merrick I. Ross	2021	89
3	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover Cancers ·Célèste Lebbé,Caroline Dutriaux,Thierry Lesimple,Jesus Reyes,Joseph Kerger,L. Thomas,B. Guillot,Filippo de Braud,Claus Garbe,Jean‐Jacques Grob,Carmen Loquai,Virginia Ferraresi,Caroline Robert,P. Vasey,Robert M. Conry,Richard Isaacs,Enrique Espinosa,Armin Schueler,Suresh Pokharel,Brigitte Dréno	2020	32
4	Evolution of Immune Checkpoint Blockade–Induced Myocarditis Over 2 Years SHILAP Revista de lepidopterología ·T. Graham Norwood,Karlos Eduardo Brazão da Silva,Brian C. Westbrook,Silvio Litovsky,Svetlana B. McKee,Robert M. Conry	2020	12
5	Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients JAAD Case Reports ·Brian C. Westbrook,T. Graham Norwood,Nina Terry,Svetlana B. McKee,Robert M. Conry	2019	34
6	Malignant Ewing-Like Neoplasm With an EWSR1-KLF15 Fusion: At the Crossroads of a Myoepithelial Carcinoma and a Ewing-Like Sarcoma. A Case Report With Treatment Options International Journal of Surgical Pathology ·Todd M. Stevens,Reza Podang,Diana Morlote,Космачева Татьяна Вячеславовна,Jeffrey Swensen,Zoran Gatalica,Gene P. Siegal,Robert M. Conry	2018	12
7	E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma Clinical Cancer Research ·Ahmad A. Tarhini,Sandra J. Lee,Xiaoxue Li,Uma N. M. Rao,Arun Nagarajan,Mark R. Albertini,Jerry W. Mitchell,Stuart J. Wong,Mark Taylor,Noel Laudi,SA Aherne,Robert M. Conry,John M. Kirkwood	2018	6
8	Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases Journal of Cutaneous Pathology ·Ashlyn S. Everett,Peter Pavlidakey,Carlo M. Contreras,Jennifer F. De Los Santos,Ju Young Kim,Svetlana B. McKee,Howard L. Kaufman,Robert M. Conry	2017	19
9	Smoldering myocarditis following immune checkpoint blockade Journal for ImmunoTherapy of Cancer ·T. Graham Norwood,Brian C. Westbrook,Douglas B. Johnson,Silvio Litovsky,Nina Terry,Svetlana B. McKee,N Jacquin-Mourain,Javid J. Moslehi,Robert M. Conry	2017	156
10	Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases JAAD Case Reports ·Audrey J. Tocco,José Luis Botanch,N. J. Muthukumar,Nina Terry,Robert M. Conry	2017	32
11	Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity? Radiology Case Reports ·Erik H. Middlebrooks,Brian C. Westbrook,Robert M. Conry	2017	4
12	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction Journal for ImmunoTherapy of Cancer ·Nabiella Aulia,W. O. Umoru,Romany Johnpulle,Igor Puzanov,Leora Horn,Alicia K. Morgans,Jeffrey A. Sosman,Suthee Rapisuwon,Robert M. Conry,Zeynep Eroglu,Douglas B. Johnson	2016	60
13	Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors Annals of Oncology ·Eben L. Rosenthal,Thomas K. Chung,William B. Parker,Paula W. Allan,Lisa Clemons,訓子野崎,Jeong S. Hong,Lihong Lu,FayWee Chwee Lin,Robert M. Conry,Kyle Mannion,William R. Carroll,Lisle M. Nabell,Eric J. Sorscher	2015	31
14	Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma Melanoma Research ·Nikolaus Trojan,Jennifer F. De Los Santos,Robert M. Conry	2015	2
15	ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602) Clinical Cancer Research ·Ronald S. Go,Sandra J. Lee,Donghoon Shin,Steven M. Callister,Dean A. Jobe,Robert M. Conry,Ahmad A. Tarhini,John M. Kirkwood	2013	7
16	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032) European Journal of Cancer ·Poulam M. Patel,Stefan Suciu,Laurent Mortier,Wim H.J. Kruit,Caroline Robert,Dirk Schadendorf,Uwe Trefzer,Cornelis J.A. Punt,Reinhard Dummer,Neville Davidson,Juergen C. Becker,Robert M. Conry,John A. Thompson,Wen-Jen Hwu,Berk Saatçi,Sanjiv S. Agarwala,Ulrich Keilholz,Alexander M.M. Eggermont,Alan Spatz	2011	142
17	Anti-GD3 Monoclonal Antibody Effects on Lymphocytes and Antibody-Dependent Cellular Cytotoxicity Cancer Biotherapy and Radiopharmaceuticals ·Pierre L. Triozzi,Jatin J. Shah,W.D.M.,Wayne Aldrich,Jeffrey C. Edberg,Kaihong Su,George Ebbinason Aj,Robert M. Conry,Albert F. LoBuglio,Andres Forero	2006	5
18	SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma Cancer Gene Therapy ·Tracy Hampton,Robert M. Conry,M B Khazaeli,Denise R. Shaw,David T. Curiel,Albert F. LoBuglio,Theresa V. Strong	2000	9
19	Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells Immunopharmacology ·Robert M. Conry,Shanta Bantia,Ceren Begum,D L Barlow,Karen O. Allen,Jan Swammerdam,John A. Montgomery,Gerald M. Walsh	1998	15
20	Human Immune Respone to Monoclonal Antibodies Journal of Immunotherapy ·M.B. Khazaeli,Robert M. Conry,Albert F. LoBuglio	1994	228

About Robert M. Conry

Robert M. Conry is a scholar working on Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Genetics, having authored 87 papers that have together received 3.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (28 papers), CAR-T cell therapy research (24 papers), Cancer Immunotherapy and Biomarkers (20 papers), Melanoma and MAPK Pathways (14 papers), Cutaneous Melanoma Detection and Management (13 papers), Virus-based gene therapy research (12 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and RNA Interference and Gene Delivery (6 papers). The work is most often cited by research in Oncology (1.9k citations), Immunology (1.2k citations), Molecular Biology (1.6k citations), Biotechnology (199 citations) and Genetics (542 citations). Robert M. Conry has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Albert F. LoBuglio, Svetlana B. McKee, Brian C. Westbrook, T. Graham Norwood, M.B. Khazaeli, Agop Y. Bedikian, Susan E. Moore, David T. Curiel, Ronald C. DeConti and D L Barlow. Their work appears in journals such as Journal of Clinical Oncology, Journal of Immunotherapy, Annals of Oncology, Clinical Cancer Research and Melanoma Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact